P&G ready to assess Teva staffing; Congress to devote fall to healthcare, FDA;

> Watch out, Teva: Now that Procter & Gamble has bought the generics-maker and sold its Pringles business, it's time for HQ to take a look at staffing levels. Story

> The House Energy and Commerce Committee's Health panel will spend the fall focused on healthcare reform regulations and preparing for a major FDA bill. Story

> Dendreon ($DNDN) has canceled its $8.3-million contract with GlaxoSmithKline ($GSK) for high-volume manufacture of the lackluster cancer vaccine Provenge, but may still be on the hook for a monthly fee of $2 million for September and October for breaching a 60-day notice requirement. Story

> Roche has unveiled a desktop continuous-random-access analyzer of chemical and biochemical parameters in aqueous solutions, intended for metabolite screening and substrate analysis. Roche release

> Big 3 drug distributor AmerisourceBergen ($ABC) has acquired IntrinsiQ, an informatics solution provider that targets community oncologists to help them make treatment decisions for their patients. Release

> Lonza Group and Shanghai Fosun Pharmaceutical Group plan to invest $15.7 million to create a joint venture in Pudong Zhangjiang High-Tech Industry Zone. Item

> Xcelience, a leader in early drug development, has expanded its equipment arsenal for clinical trial supply manufacturing and packaging. Xcelience release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.